UR-13870 is a p38 mitogen-activated protein kinase (MAPK) inhibitor potentially for the treatment of autoimmune disease and neuropathic pain. UR-13870 treatment significantly reduced OX-42, metabotropic glutamate type 5 receptor (mGluR5), and NMDA (N-methyl-d-aspartate) 2B subunit receptor (NR2B) expression in the anterior cingulate cortex after spinal cord injury. UR-13870 treatment significantly decreased hindlimb hyperreflexia to both mechanical and cold stimuli after spared nerve injury without loss of general motor function, in addition to a reduction in pain-related anxiety behavior at day 21 after spared nerve injury, accompanied by normalization of OX-42 immunoreactivity within the ipsilateral lumbar dorsal horn. References: Galan-Arriero I, Avila-Martin G, Ferrer-Donato A, Gomez-Soriano J, Bravo-Esteban E, Taylor J. Oral administration of the p38α MAPK inhibitor, UR13870, inhibits affective pain behavior after spinal cord injury. Pain. 2014 Oct;155(10):2188-98. doi: 10.1016/j.pain.2014.08.030. PubMed PMID: 25180015.

纯度：≥98%

CAS：755753-89-0